Infectious Diseases News and Research

RSS

Nomogram helps predict anal cancer risk in HIV patients

Both cervical and anal cancer are caused by human papillomavirus. Both diseases also share a common precursor: abnormal cells known as high-grade squamous intraepithelial lesions (HSIL).

1 Jul 2022

Most therapeutic antibodies for treating COVID-19 patients do not inhibit emerging Omicron subvariants

The Omicron subvariants BA.1 and BA.2 of SARS-CoV-2 have dominated the COVID-19 pandemic in early 2022. In many countries, these viruses are now outcompeted by emerging subvariants, with BA.5 being responsible for the current uptick of cases in Germany.

1 Jul 2022

New antibody-based method for SARS-CoV-2 detection does not require a blood sample

Despite significant and stunning advances in vaccine technology, the COVID-19 global pandemic is not over. A key challenge in limiting the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is identifying infected individuals.

1 Jul 2022

HIV accelerates epigenetic aging soon after initial HIV infection

HIV has an "early and substantial" impact on aging in infected people, accelerating biological changes in the body associated with normal aging within just two to three years of infection, according to a study by UCLA researchers and colleagues.

1 Jul 2022

Stopping a pervasive bacterium that makes millions sick each year

As we head outdoors this summer, scientists are working to clip the long, flexible appendages that enable the common bacterium Campylobacter jejuni to make its way from undercooked poultry and natural waterways into our intestinal tract where it makes millions of us sick each year.

1 Jul 2022

Omicron subvariants BA.2.12.1, BA.4, and BA.5 show higher neutralization resistance to antibodies

In a recent study published in The Lancet Infectious Diseases, researchers investigated the neutralization sensitivity of the emerging Omicron sub-variants, BA.2.12.1, BA.4, and BA.5.

30 Jun 2022

Novel universal flu vaccine confers protection against different strains and subtypes of influenza A viruses

A new universal flu vaccine constructed with key parts of the influenza virus offers broad cross protection against different strains and subtypes of influenza A viruses in young and aged populations, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.

30 Jun 2022

Anticancer drug candidate that targets a human protein could be a pan-viral medication

More than two years into the COVID-19 pandemic, people are realizing that the "new normal" will probably involve learning to co-exist with SARS-CoV-2. Some treatments are available, but with new variants emerging, researchers are looking toward new strategies.

29 Jun 2022

Acute COVID-19 and vaccination induce cross-reactive antibody responses in breast milk

IgA and IgG in human breast milk and blood were assessed for their activity against SARS-CoV-2 and SARS-CoV-1, as well as four other prevalent HCoVs.

28 Jun 2022

UMass Amherst assistant professor wins $1.4 million grant to engineer synthetic bacteria for water contaminant removal

Lauren Andrews, University of Massachusetts Amherst assistant professor and the Marvin and Eva Schlanger Faculty Fellow in the department of chemical engineering, has received a three-year, $1.4 million grant from the National Science Foundation for a collaborative project to engineer synthetic bacteria to neutralize toxic contaminants found in drinking water.

28 Jun 2022

Phase 1 clinical trial of new influenza vaccine begins at NIH Clinical Center in Bethesda

A Phase 1 clinical trial of a novel influenza vaccine has begun inoculating healthy adult volunteers at the National Institutes of Health Clinical Center in Bethesda, Maryland.

28 Jun 2022

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to Mayo Clinic researchers.

28 Jun 2022

SARS-CoV-2 virus undertakes a massive takeover of the body's fat-processing system

The virus that causes COVID-19 undertakes a massive takeover of the body's fat-processing system, creating cellular storehouses of fat that empower the virus to hijack the body's molecular machinery and cause disease.

28 Jun 2022

Infectious period in healthy, vaccinated adults with SARS-CoV-2 is limited, study finds

In January 2022, the U.S. shifted its guidelines to recommend isolation of five days from COVID-19 symptom onset, followed by an additional five days of mask wearing.

27 Jun 2022

Rensselaer scientists secure $3.5 million grant to develop a low-dose, oral COVID antiviral drug

Rensselaer Polytechnic Institute researchers Gaetano Montelione and Christopher Cioffi will use a five-year, $3.5 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to develop a low-dose, oral COVID antiviral drug that can be administered at home.

27 Jun 2022

Infectious Diseases News and Research

Nomogram helps predict anal cancer risk in HIV patients

Most therapeutic antibodies for treating COVID-19 patients do not inhibit emerging Omicron subvariants

New antibody-based method for SARS-CoV-2 detection does not require a blood sample

HIV accelerates epigenetic aging soon after initial HIV infection

Stopping a pervasive bacterium that makes millions sick each year

Omicron subvariants BA.2.12.1, BA.4, and BA.5 show higher neutralization resistance to antibodies

Novel universal flu vaccine confers protection against different strains and subtypes of influenza A viruses

Anticancer drug candidate that targets a human protein could be a pan-viral medication

Acute COVID-19 and vaccination induce cross-reactive antibody responses in breast milk

UMass Amherst assistant professor wins $1.4 million grant to engineer synthetic bacteria for water contaminant removal

Phase 1 clinical trial of new influenza vaccine begins at NIH Clinical Center in Bethesda

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

SARS-CoV-2 virus undertakes a massive takeover of the body's fat-processing system

Infectious period in healthy, vaccinated adults with SARS-CoV-2 is limited, study finds

Rensselaer scientists secure $3.5 million grant to develop a low-dose, oral COVID antiviral drug

Persistent fatigue post-COVID-19 in pregnant women

UK announces £25 million to better prepare for future devastating pandemics

Antibody profiles of internal viral proteins predict severe COVID-19 outcomes

Updated Cochrane Review: No evidence to support the use of ivermectin for treating COVID-19 infection

Techniques used in weather forecasting can be repurposed to assess risk of COVID-19 exposure

eBook: Advancing infectious disease vaccine development eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News